Litcius/Paper detail

Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update

Robert Roskoski

2021Pharmacological Research332 citationsDOI

Topics & Concepts

PharmacologyMedicineTyrosine kinaseKinaseImatinibCancer researchChemistryInternal medicineReceptorBiochemistryMyeloid leukemiaChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchPI3K/AKT/mTOR signaling in cancer
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update | Litcius